StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on BLRX. HC Wainwright boosted their target price on shares of BioLineRx from $9.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Jones Trading reiterated a “hold” rating on shares of BioLineRx in a report on Wednesday, April 2nd.

BioLineRx Stock Performance

Shares of BioLineRx stock opened at $3.24 on Friday. The company has a market capitalization of $10.79 million, a PE ratio of -0.37 and a beta of 1.15. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The company has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $6.39. BioLineRx has a one year low of $2.30 and a one year high of $35.60.

Hedge Funds Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC bought a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.